Korea Investment & Securities has projected that Samsung Biologics will see earnings growth due to its acquisition of PolyPeptide Group (PPGN) and the commercial production at its fifth plant. However, the firm noted that the existing plants have already reached high operational rates, leading to a slowdown in growth. They emphasized the need to resolve labor disputes and secure large orders for additional growth momentum. The investment recommendation remains a 'buy' with a target price of 1.95 million won.
Analyst Wi Hae-joo forecasted in a report on November 13 that Samsung Biologics' revenue for 2027 will increase by 14% year-on-year to 6.3297 trillion won, with operating profit expected to rise by 11% to 2.6203 trillion won. The anticipated operating profit margin is 41%.
Wi explained that since the first through fourth plants are expected to reach full operation in 2026, future profit growth will be driven by increased utilization of the fifth plant and operations at the U.S. facility.
The U.S. plant is currently operating at about 50% capacity, expected to reach breakeven levels. The fifth plant is set to begin commercial production in the second half of next year, with an expected utilization rate of 16% and projected revenue of 289 billion won. Significant profit growth effects are anticipated starting in 2028.
The potential for earnings expansion from the PPGN acquisition is viewed positively. Samsung Biologics plans to complete its capital increase and the PPGN acquisition process by the end of the year.
The company also expects to benefit from the growth of the obesity treatment market. PPGN generated 57% of its revenue in 2025 from the production of peptides related to metabolic diseases. Among the 37 ongoing metabolic disease projects, seven are in Phase 3 clinical trials, indicating potential for additional orders upon commercialization.
Wi projected that if PPGN's commercialization and late-stage clinical orders for metabolic diseases expand and operational efficiency improves, the standalone operating profit margin could rise to 20% by 2028.
However, labor disputes and the possibility of order delays are identified as risk factors. In the contract manufacturing organization (CMO) business, supply chain stability and labor relations are critical evaluation factors for clients, meaning that resolving conflicts could impact new orders.
Uncertainties surrounding U.S. regulations on China's WuXi AppTec also pose a variable. Wi noted that news of WuXi AppTec's removal from the list of Chinese military enterprises has had a somewhat negative impact on Samsung Biologics' stock price. The decision by the U.S. Office of Management and Budget (OMB) regarding the designation of concerned companies on December 18 could also influence investor sentiment.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.